Forte Biosciences Inc FBRX

Healthcare Biotechnology

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.

NDAQ:FBRX - Post by User

Forte Biosciences Inc

<< Previous

Bullboard Posts

Next >>

Post by MarketEngine17on Nov 20, 2024 12:32pm

24 Views

Post# 36322007

Forte Secures 53M Boost for Autoimmune Breakthroughs in 2025

With $53 million raised through an oversubscribed equity financing, Forte has secured support from major institutional investors such as OrbiMed and Janus Henderson. These funds will drive the advancement of FB102, their key candidate targeting autoimmune diseases. As the celiac disease trial progresses and new indications are planned, Forte looks set for significant breakthroughs in 2025.

<< Previous

Bullboard Posts

Next >>

Options trading in a volatile macro environment